Ondine Biomedical Inc.
LSE : OBP

April 15, 2011 08:59 ET

Ondine to Participate in Vancouver General Hospital Infection Control Quality Improvement Project

FOR: ONDINE BIOMEDICAL INC.

TSX, AIM SYMBOL: OBP

April 15, 2011

Ondine to Participate in Vancouver General Hospital Infection Control Quality Improvement Project

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 15, 2011) - Ondine Biomedical Inc. ("Ondine" or the "Company")

(TSX:OBP)(AIM:OBP) today announced that it has agreed to supply Vancouver General Hospital (VGH) with Ondine's

MRSAid(TM) Photodisinfection System for nasal pathogen decolonization as part of a thirteen month infection

control Quality Improvement Project ("QIP") being conducted at the hospital. This project, championed by Dr.

Elizabeth Bryce, Regional Medical Director, Infection Control, Vancouver Coastal Health, is being undertaken

with the objective of reducing the incidence of surgical site infections (SSIs) in selected surgical

populations. Patients treated under this initiative will include those undergoing cardiac, spinal, orthopedic,

thoracic, vascular, breast reconstruction, and neurological surgeries. The QIP, which is being sponsored by VGH

& UBC Hospital Foundation funding of approximately $675,000, will focus on pre-surgical pathogen decolonization

using photodisinfection of the nasal passages and full body chlorhexidine wipes for all patients treated under

this initiative.

"We are excited to be collaborating on this QIP which will utilize MRSAid(TM), Ondine's non-antibiotic nasal

pathogen decolonization system," stated Dr Bryce. "Surgical site infections are responsible for longer patient

recovery times and significant costs to the health care system. In certain cases, these infections can result

in patient mortality due to the presence of highly antibiotic resistant pathogens."

Dr. Cale Street of Ondine stated: "Photodisinfection provides a rapid, powerful antibacterial modality that

does not generate bacterial resistance. The 10 minute, simple, painless MRSAid(TM) procedure is undertaken at

the hospital at the time of preparation for surgery, and represents a promising approach to decolonization of

acute care patients in healthcare facility settings. The MRSAid(TM) Photodisinfection System is designed to

reduce hospital-acquired infections among high risk patients while eliminating patient compliance and

antibiotic resistance concerns associated with currently used topical antibiotics."

About Ondine Biomedical Inc.

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and

viral infections. The Company is focused on developing leading edge products utilizing its patented light-

activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection

provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic

resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development

laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at:

www.ondinebio.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and

other similar expressions, are forward-looking statements that involve a number of risks and uncertainties.

Factors that could cause actual results to differ materially from those projected in the Company's forward-

looking statements include the following: market acceptance of our technologies and products; our ability to

obtain financing; our financial and technical resources relative to those of our competitors; our ability to

keep up with rapid technological change; government regulation of our technologies; our ability to enforce our

intellectual property rights and protect our proprietary technologies; the ability to obtain and develop

partnership opportunities; the timing of commercial product launches; the ability to achieve key technical

milestones in key products and other risk factors identified from time to time in the Company's public filings.

-30-

FOR FURTHER INFORMATION PLEASE CONTACT:

Ondine Biomedical Inc.

Carolyn Cross

Chairman and CEO

ccross@ondinebio.com

www.ondinebio.com

OR

Canaccord Genuity Limited, Nominated Adviser

Mark Williams/Bhavesh Patel

+4420 7050 6500

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this

release.

-0-

Contact Information

  • Ondine Biomedical Inc.